Tsumura & Co banner

Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 3 688 JPY -0.05% Market Closed
Market Cap: ¥283.1B

EV/EBIT

9.1
Current
8%
Cheaper
vs 3-y average of 9.8

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
9.1
=
Enterprise Value
¥360.6B
/
EBIT
¥36.6B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
9.1
=
Enterprise Value
¥360.6B
/
EBIT
¥36.6B

Valuation Scenarios

Tsumura & Co is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (9.8), the stock would be worth ¥4 012.24 (9% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+93%
Average Upside
41%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 9.1 ¥3 688
0%
3-Year Average 9.8 ¥4 012.24
+9%
5-Year Average 10 ¥4 084.51
+11%
Industry Average 17.5 ¥7 116.09
+93%
Country Average 13.6 ¥5 554.81
+51%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
JP
Tsumura & Co
TSE:4540
274.9B JPY 9.1 9.5
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 30.2 41.8
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 21.6 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 12.9 19.3
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 22.7 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 15.9 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 11.8 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.3 10.7
US
Pfizer Inc
NYSE:PFE
152.4B USD 10 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 8.8 16.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBIT: 102
9.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.2
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.6
13%
1.7
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
22.7
21%
1.1
CH
Novartis AG
SIX:NOVN
15.9
9%
1.8
US
Merck & Co Inc
NYSE:MRK
11.8
6%
2
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
US
Pfizer Inc
NYSE:PFE
10
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
P/E Multiple
Earnings Growth PEG
JP
Tsumura & Co
TSE:4540
Average P/E: 20.8
9.5
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
41.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.1
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1

Market Distribution

Lower than 75% of companies in Japan
Percentile
25th
Based on 4 801 companies
25th percentile
9.1
Low
0.1 — 9.8
Typical Range
9.8 — 18.1
High
18.1 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 9.8
Median 13.6
70th Percentile 18.1
Max 414 821 439

Tsumura & Co
Glance View

Market Cap
283.1B JPY
Industry
Pharmaceuticals

Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.

Intrinsic Value
3 472.39 JPY
Overvaluation 6%
Intrinsic Value
Price ¥3 688
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett